T13 · Trade opportunity evidence

China (CHN) to POL (POL) medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale (HS6 300431)

A country-to-country view of reported medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale trade, combining buyer demand, exporter position, market structure, access conditions, and observed lane history.

Exporter China (CHN)Importer POL (POL)HS6 300431One-way tradeCoverage 2020-2024Growing

3-year buyer projection

$210.1MCalculated from reported demand

Exporter growth

+21.8%Full available history

Suppliers in market

15Latest reported count

Observed history

5 yearsLast year: 2024

Reported observations

What this medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale lane shows for HS 300431

Core values for China (CHN) → POL (POL) in HS 300431.

Buyer market

Latest imports$172.8M
Five-year projection$239.4M
Buyer CAGR+6.7%
Latest annual change+36.7%

Exporter position

Latest exports$291.9K
Market share0.2%
Share change-0.4 pp
Best observed share36.8%

Market structure

Reported suppliers15
Concentration index2,581.2
Share gap+36.6 pp
SignalGrowing

Detailed evidence

Complete lane evidence

Reported values, calculated indicators, and country-pair context for this route.

MeasureValueWhat it describes
Buyer imports$172.8MPOL (POL)'s latest reported imports
Exporter exports$291.9KChina (CHN)'s exports to POL (POL)
Exporter market share0.2%Exporter share of the reported buyer market
Buyer five-year CAGR+6.7%Annualized change in buyer imports
Exporter full-history CAGR+21.8%Annualized change in exporter exports
Three-year buyer projection$210.1MCalculated projection from reported demand
Five-year buyer projection$239.4MCalculated projection from reported demand
Average buyer imports$111.7MAverage reported importer value
Peak buyer imports$187.6MHighest reported importer value
Average exporter exports$605.3KAverage reported lane exports
Peak exporter exports$1.0MHighest reported lane exports
Share change-0.4 ppLatest one-year change in exporter share
Reported suppliers15Supplier countries observed in the latest period
Buyer GDP$674.0BLatest buyer-country GDP estimate
Buyer GDP per person$17.8KLatest buyer-country GDP per person
Buyer population37,781 thousandLatest buyer-country population estimate
Buyer investment rate22.7%Reported buyer-country investment rate
Buyer secondary education93.8%Reported secondary education coverage
Distance6,948 kmApproximate country-pair distance
Business entry time37 daysReported days to start a business
Shared legal systemYesCountry-pair institutional relationship
Reported FTANoReported trade-agreement indicator
WTO memberYesBuyer-country WTO membership indicator
Lane volatility0.6Variation indicator across observed lane values
Maximum drawdown71.6%Largest observed decline from a prior peak
Observed history5 yearsCoverage through 2024

Research reading

Medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale demand and the China (CHN) to POL (POL) lane

POL (POL) reported $172.8M of medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale imports in 2024. China (CHN) accounted for 0.2% of the observed market and reported $291.9K in exports on this lane.

The latest annual values eased slightly, while the longer available history shows +6.7% buyer growth and +21.8% exporter growth. The page separates reported values from projections and indicators.

Product classification

What does HS 300431 include?

HS 300431 covers Medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale. This page studies the six-digit Harmonized System classification rather than a company, brand, retail category, or individual shipment.

The classification sits in HS chapter 30 and heading 3004. The recorded trade type is one-way trade, with a high price range classification in the available product reference data.

How to interpret this page

Compare demand, position, and history together

This HS 300431 trade opportunity page brings together the buyer market in POL (POL), the exporter position of China (CHN), and the observed conditions of their trade lane. A large buyer market does not by itself show that every exporter has equal access, and a positive growth rate does not remove the need to examine volatility and historical coverage.

Use the reported imports and exports to understand scale, market share to understand position, projections to understand the calculated forward view, and lane history to understand how much evidence supports the comparison.

Frequently asked questions

Questions about China (CHN) to POL (POL) medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale trade

What is the HS code for this product?

This page covers HS 300431, the six-digit product classification shown in the trade records.

How large is the POL (POL) market?

The page reports the latest buyer imports, historical averages, peaks, growth, and calculated projections for medicaments: containing insulin, for therapeutic or prophylactic uses, packaged for retail sale.

How strong is China (CHN) in this market?

Exporter performance is shown through lane exports, market share, share change, growth, and the number of reported suppliers.

What should be checked before entering this market?

Review market scale, competition, access indicators, volatility, drawdown, and the available history together rather than relying on one signal.

Definitions and coverage

How to read this page

Reported values

Trade values describe reported merchandise trade for the stated HS6 classification. They are not company-level sales or shipment records.

Calculated indicators

Growth, projections, concentration, volatility, and share-gap figures are calculated from the reported observations and should be interpreted with their coverage period.

Coverage

This sample covers 5 observed years through 2024. Missing values are shown as not reported rather than estimated.